Carlsmed (NASDAQ:CARL) Given Buy Rating at Truist Financial

Truist Financial restated their buy rating on shares of Carlsmed (NASDAQ:CARL) in a research note released on Friday,Benzinga reports. They currently have a $20.00 price target on the stock, up from their previous price target of $18.00.

Other equities research analysts have also recently issued reports about the stock. BTIG Research increased their target price on shares of Carlsmed from $21.00 to $24.00 and gave the company a “buy” rating in a research report on Friday. Weiss Ratings assumed coverage on shares of Carlsmed in a research report on Thursday, October 16th. They set a “sell (e)” rating on the stock. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Carlsmed currently has a consensus rating of “Hold” and a consensus target price of $22.00.

Carlsmed Stock Up 14.9%

Shares of CARL stock traded up $1.77 on Friday, reaching $13.66. 123,375 shares of the company were exchanged, compared to its average volume of 54,348. Carlsmed has a 1 year low of $11.76 and a 1 year high of $16.20. The firm has a 50-day moving average of $13.59.

Carlsmed (NASDAQ:CARL) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.05. Carlsmed has set its FY 2025 guidance at EPS.

Institutional Trading of Carlsmed

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. purchased a new position in shares of Carlsmed during the third quarter worth $37,000. Rhumbline Advisers acquired a new position in Carlsmed during the 3rd quarter worth about $79,000. Board of Trustees of The Leland Stanford Junior University purchased a new position in Carlsmed during the 3rd quarter valued at about $335,000. Kornitzer Capital Management Inc. KS purchased a new stake in Carlsmed during the third quarter worth about $736,000. Finally, TD Waterhouse Canada Inc. acquired a new stake in shares of Carlsmed during the third quarter worth about $2,026,000.

Carlsmed Company Profile

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).